TY - GEN
T1 - Protein expression profile of celiac disease patient with aberrant T cell by two-dimensional difference gel electrophoresis
AU - De Re, Valli
AU - Simula, Maria Paola
AU - Caggiari, Laura
AU - Ortz, Nicoletta
AU - Spina, Michele
AU - Da Ponte, Alessandro
AU - De Appolonia, Leandro
AU - Dolcetti, Riccardo
AU - Canzonieri, Vincenzo
AU - Cannizzaro, Renato
PY - 2007/8
Y1 - 2007/8
N2 - One complication of celiac disease (CD) is refractory CD. These patients frequently show aberrant intraepithelial T cell clones and an increasing risk of evolution into enteropathy-associated T cell lymphoma (EATL). There is debate in the literature whether these cases are actually a smoldering lymphoma from the outset. The mechanism inducing T cell proliferation and prognosis remains unknown. Recently, alemtuzumab has been proposed as a promising new approach to treat these patients. Only few single cases have been tested presently, nevertheless, in all of them a clinical improvement has been observed, while intraepithelial lymphocytes (IELs) effectively targeted by alemtuzumab are still a debated issue. Using 2D-DIGE, we found hyperexpressed proteins specifically associated with aberrant T cell in a patient with CD by comparing the protein expression with that of patients with CD and polyclonal T cell or with that of control subjects (patients with polyclonal T cell and no CD). Proteins with a higher expression in duodenal biopsy of the patient with aberrant T cell were identified as IgM, apolipoprotein C-III, and Charcot-Leyden crystal proteins. These preliminary data allow hypothesizing different clinical effects of alemtuzumab in patients with CD, since besides the probable effect of alemtuzumab on T cell, it could effect inflammatory-associated CD52+ IgM+ B cell and eosinophils cells, known to produce IgM and Charcot-Leyden crystal proteins, which we demonstrated to be altered in this patient. Results also emphasize the possible association of apolipoprotein with aberrant T cell proliferation.
AB - One complication of celiac disease (CD) is refractory CD. These patients frequently show aberrant intraepithelial T cell clones and an increasing risk of evolution into enteropathy-associated T cell lymphoma (EATL). There is debate in the literature whether these cases are actually a smoldering lymphoma from the outset. The mechanism inducing T cell proliferation and prognosis remains unknown. Recently, alemtuzumab has been proposed as a promising new approach to treat these patients. Only few single cases have been tested presently, nevertheless, in all of them a clinical improvement has been observed, while intraepithelial lymphocytes (IELs) effectively targeted by alemtuzumab are still a debated issue. Using 2D-DIGE, we found hyperexpressed proteins specifically associated with aberrant T cell in a patient with CD by comparing the protein expression with that of patients with CD and polyclonal T cell or with that of control subjects (patients with polyclonal T cell and no CD). Proteins with a higher expression in duodenal biopsy of the patient with aberrant T cell were identified as IgM, apolipoprotein C-III, and Charcot-Leyden crystal proteins. These preliminary data allow hypothesizing different clinical effects of alemtuzumab in patients with CD, since besides the probable effect of alemtuzumab on T cell, it could effect inflammatory-associated CD52+ IgM+ B cell and eosinophils cells, known to produce IgM and Charcot-Leyden crystal proteins, which we demonstrated to be altered in this patient. Results also emphasize the possible association of apolipoprotein with aberrant T cell proliferation.
KW - 2D-DIGE
KW - Celiac disease
KW - Enteropathy-associated T cell lymphoma
KW - T cell receptor
UR - http://www.scopus.com/inward/record.url?scp=34848862206&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34848862206&partnerID=8YFLogxK
U2 - 10.1196/annals.1398.049
DO - 10.1196/annals.1398.049
M3 - Conference contribution
C2 - 17785332
AN - SCOPUS:34848862206
SN - 1573316636
SN - 9781573316637
VL - 1109
T3 - Annals of the New York Academy of Sciences
SP - 429
EP - 440
BT - Annals of the New York Academy of Sciences
ER -